TNP-ATP tetrasodium 

TNP-ATP is an antagonist of purinergic P2Y1, P2X3, and P2X2/3 receptors (IC₅₀ = 6, 0.9, and 7 nM, respectively, in HEK293 cells expressing human receptors). TNP-ATP reduces acetate-induced calcium flux in 1321N1 cells expressing P2X3 and P2X2/3 receptors (IC₅₀ = 100 and 62 nM, respectively). TNP-ATP dose-dependently attenuates acetate-induced abdominal contractions in a mouse visceral pain model (ED₅₀ = 6.35 µmol/kg)^[1][2].

806.20

C₁₆H₁₃N₈Na₄O₁₉P₃

O=[N](C(C1(C([N](=O)=O)=C2)O[C@]([C@@](N3C4=NC=NC(N)=C4N=C3)([H])O[C@@H]5CO[P](O[P](O[P](O[Na])(O[Na])=O)(O[Na])=O)(O[Na])=O)([H])[C@]5([H])O1)=CC2[N](=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Honore P, et al. TNP-ATP, a potent P2X3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics. Pain. 2002 Mar;96(1-2):99-105.  [Content Brief]

  [2]. Virginio C, et al. Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73.  [Content Brief]